CRNX - Crinetics Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5359.66M
Enterprise Value 3211.22M
Trailing P/E N/A
Forward P/E 1-4.83
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)301.47
Price/Book (mrq)3.03
Enterprise Value/Revenue 3177.05
Enterprise Value/EBITDA 6-3.99

Trading Information

Stock Price History

Beta (5Y Monthly) N/A
52-Week Change 3-43.20%
S&P500 52-Week Change 3-14.06%
52 Week High 328.81
52 Week Low 310.63
50-Day Moving Average 317.17
200-Day Moving Average 319.38

Share Statistics

Avg Vol (3 month) 371.39k
Avg Vol (10 day) 3144k
Shares Outstanding 524.2M
Float 8.1M
% Held by Insiders 15.59%
% Held by Institutions 197.76%
Shares Short (Mar. 12, 2020) 41.55M
Short Ratio (Mar. 12, 2020) 433.18
Short % of Float (Mar. 12, 2020) 418.24%
Short % of Shares Outstanding (Mar. 12, 2020) 46.29%
Shares Short (prior month Feb. 13, 2020) 41.61M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec. 30, 2019
Most Recent Quarter (mrq)Dec. 30, 2019

Profitability

Profit Margin 0.00%
Operating Margin (ttm)-4,512.32%

Management Effectiveness

Return on Assets (ttm)-22.30%
Return on Equity (ttm)-36.36%

Income Statement

Revenue (ttm)1.19M
Revenue Per Share (ttm)0.05
Quarterly Revenue Growth (yoy)-58.90%
Gross Profit (ttm)-40.31M
EBITDA -52.95M
Net Income Avi to Common (ttm)-50.42M
Diluted EPS (ttm)-2.09
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)118.39M
Total Cash Per Share (mrq)4.82
Total Debt (mrq)5.57M
Total Debt/Equity (mrq)4.76
Current Ratio (mrq)14.79
Book Value Per Share (mrq)4.83

Cash Flow Statement

Operating Cash Flow (ttm)-46.38M
Levered Free Cash Flow (ttm)-29.4M